How about the $33 April 22 calls at 85 cents?
They have to expect a Friday close above $34 to make any money.
I think it will be there.
And how about the call volume at $35, 35.50 and 36,00?
Cramer is Wall Street's tool.
I doubt they will allow a viewer's question.
Let us know first mention of SKX from the blowhard.
I can't watch all the time.
The last I see:
Skechers USA (SKX) Weak On High Volume Today By TheStreet Wire 10:04 AM EDT 03/22/16 Trade-Ideas LLC identified Skechers USA (SKX) as a weak on high relative volume candidate
Tomorrow will be a different story.
Cramer will NOT invite SKX to his show in order to protect
the DARK SIDE (shorts) from the outstanding SKX results.
Believe it or not!
Check it out: Jim Cramer: Choose Nike Over Skechers (SKX) Stock
It's up $2.10 to $32.90, after hours, a 6.4% increase.
I expect $34 tomorrow and your $42 in three months.
I hope Cramer stays out of this!
He's the LAST talking head we need!
All the Street talk has been about NKE , UA and adidas.
Let's watch them jump on the SKX band wagon.
shenze, a little school for you:
dextromethorphan hydrobromide and quinidine sulfate
SIMPLE and patent protected
and Acquired By Otsuka Pharmaceutical For $3.5 Billion
Doctors who prescribe and pharmacists who fulfill Belphen and Contrave copies,
open themselves to law suits. Most will not take on that liability to save a few bucks.
shenze, by definition a new drug must be novel to obtain a patent. Is English your
first language? Study the history of Avanir for their "cough medicine" success.
The same Judge Stark's court is currently protecting OREX's patent from the
generic predators. This isn't India where people can't even afford the stolen
medical technology their companies almost give away.
How's Arena's Belphen development coming?
They couldn't afford their own COVT?
They know , like the NOVEL Contrave (yes it is patented), it would work better than Belviq.
"blew off" ? OREX had to pay Tekada $60 million (done) and future royalties
to get rid of them and free up US rights.
shenzebengal, pick your poison (from one web site)
More common side effects using Contrave
Blurred vision,discouragement,dizziness,fear or nervousness,feeling sad or empty,headache,
irritability,lack of appetite,loss of interest or pleasure, pounding in the ears,slow or fast heartbeat,tiredness,trouble concentrating, trouble sleeping.
More common side effects using Belviq
Anxiety,bladder pain,bloody or cloudy urine,blurred visionbody aches or pain, chills,cold sweats,coma,confusion,cool, pale skin,cough,depression ,difficult, burning, or painful urination,
difficulty with breathing,dizziness , ear congestion,fast heartbeat,fever,frequent urge to urinate,
headache, increased hunger,loss of voice,lower back or side pain,nasal congestion,
nausea nightmares pounding in the ears,runny nose,seizures,shakiness,slow or fast heartbeat,
slurred speech,sneezing,sore throatswelling of the breasts or breast soreness in both females and males,unexpected or excess milk flow from the breasts,unusual tiredness or weakness.
That's right. The 180 are calendar days (6 months) and management can request another 6 months if,
at the end of the first period they meet all of the other listing requirements.
You do not know what you are talking about!
"OREX Has 3 More Days To Push The Share Price Over $1.00 Before NASDAQ Issues The Delisting Warning. by shenzebengal •Mar 23, 2016 8:31 AM
Do you know what "TRADING days" means?
When the thirty TRADING days warning is given, OREX has 180 more TRADING days to correct the situation.
My point is, that for someone who "has no interest", a basher has to post accuately to be taken seriously.
on purpose? Is he just that dumb? But he really doesn't care, just clutters this message board.
If a company is in violation of the continued listing standards for a period of 30 consecutive TRADING days, NASDAQ sends a "deficiency notice." The most common reasons for a deficiency notice are a share price that falls below $1.00 or a market cap that falls below the stated minimum (as low #$%$ million if other requirements are satisfied).
Once a deficiency notice has been sent, the company has 180 TRADING days if the violation was for a sub-$1.00 share price. In order to be compliant, the company's share price or market cap must rise above the minimum for at least 10 consecutive days in the 180-TRADING day period.
I can't find Sketchers, but:
"Among the companies to which Sports Authority is most indebted are Nike Inc., owed the largest sum of all athletic brands at $47.9 million, and Asics America Corp., owed $23.3 million. Under Armour Inc. follows closely behind Asics, with an unsecured claim of $23.2 million. Implus Footwear LLC, a manufacturer of footwear and recreational accessories for brands like New Balance and Yaktrak, is owed $9.4 million, and Agron Inc., a licensed dealer for Adidas products such as socks, hats, bags and other sporting goods accessories, is due $9.2 million.
Adidas’ golf business, TaylorMade Adidas Golf, also makes the list of Sports Authority creditors, with a claim to $2.5 million. Brooks Sports Inc. is owed $2 million, and New Balance is due $1.6 million."
Checking the Sacramento Sports Authority, Nike sells 5,354 items, of which 594 are footwear.
Sketchers sells 51 items, of which 29 are footwear. Sports Authority's bankruptcy papers show
that they owe Nike $48M.